US Market News
3週前
Sharps Technology Reports Continued Growth in Q1 2026 Highlighting Strengthened Balance Sheet and Strong Treasury ExecutionMay 15, 2026 8:00 AM
PR Newswire (US) NEW YORK, May 15, 2026 /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company"), a medical device sales and distribution company that has adopted a Solana-based digital asset treasury strategy, has announced financial results for the first quarter ended March 31, 2026, and provided an update on the continued execution of its treasury and infrastructure strategy. "The first quarter of 2026 shows that the strategic repositioning we completed last year is continuing to translate into meaningful financial performance," said Paul K. Danner, Executive Chairman of Sharps. "We begin the second quarter with a treasury that is actively generating yield, giving us the financial flexibility to advance the next phase of our strategy - one focused on scaling shareholder value and unlocking new sources of recurring income over time."Key Highlights from Q1 2026:As of March 31, 2026, STSS held approximately 2 million SOL in its treasury.The Company's cash balance was approximately $12.3 million as of March 31, 2026.The Company had total revenue of approximately $3.3 million for Q1 2026, including $3.1 million in net staking revenue, which represented an approximately 6% gross annualized validator staking yield, and $0.2 million in product revenue from medical device distribution.The Company enters the second quarter of 2026 with a productive digital asset treasury and continued institutional relevance within the Solana ecosystem. Management believes the Company is positioned to utilize our effective treasury execution as the foundation to support broader strategic initiatives intended to enhance the Company's long-term growth profile and open additional opportunities for future revenue generation.For more detailed information, please refer to the Quarterly Report on Form 10-Q for the three months ended March 31, 2026 filed with the U.S. Securities and Exchange Commission, and accessible at www.sec.gov.Forward Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the Company's execution of its Solana digital asset treasury strategy and the potential opportunities such initiatives may create for retail and institutional audiences. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include, among others: the Company's ability to successfully execute its Solana treasury strategy; volatility in the market price of SOL and other digital assets; changes in the regulatory or legal environments; competitive pressures; and general market, economic, and business conditions. Additional risks are described in the "Risk Factors" section of the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov.Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.About Sharps TechnologySharps Technology is a medical device sales and distribution company that has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain. For additional information, please visit the Company's website www.sharpstechnology.com.Contactir@sharpstechnology.com View original content to download multimedia:https://www.prnewswire.com/news-releases/sharps-technology-reports-continued-growth-in-q1-2026-highlighting-strengthened-balance-sheet-and-strong-treasury-execution-302772959.htmlSOURCE Sharps Technology Inc Original: Sharps Technology Reports Continued Growth in Q1 2026 Highlighting Strengthened Balance Sheet and Strong Treasury Execution
US Market News
3週前
Sharps Technology Adopts Limited Duration Stockholder Rights PlanMay 14, 2026 6:07 PM
PR Newswire (US) MELVILLE, N.Y., May 14, 2026 /PRNewswire/ -- Sharps Technology, Inc. ("Sharps Technology" or the "Company") (NASDAQ: STSS) today announced that its Board of Directors has adopted a limited duration stockholder rights plan (the "Rights Plan") to protect stockholder interests. The Board adopted the Rights Plan following recent accumulations of the Company's common stock in order to protect the interests of the Company and its stockholders. The Rights Plan is intended to better ensure that all stockholders have the opportunity to realize the value of their investment. Further, it is designed to reduce the likelihood that any person or group could obtain control of the Company through open market accumulation or other tactics without paying an appropriate control premium. The Rights Plan also provides the Board with sufficient time to make informed judgments and take actions that are in the best interests of the Company and its stockholders. It does not deter the Board from considering any offer or proposal that is fair and otherwise in the best interest of Sharps Technology's stockholders."The Board determined that adopting the Rights Plan is a prudent measure to guard against tactics to gain control of Sharps Technology without appropriately recognizing the full value of the Company," said Paul Danner, Executive Chair of the Board. "We remain focused on executing our transformational strategy and taking actions that we believe will drive long-term value for all stockholders."In connection with the Rights Plan, Sharps Technology will issue, by means of a dividend, one preferred share purchase right for each outstanding share of Sharps Technology common stock to stockholders of record as of the close of business on May 26, 2026. Initially, these rights will not be exercisable and will trade with, and be represented by, the shares of Sharps Technology common stock. The Rights Plan has an expiration date of May 12, 2027, although the Board may consider whether to terminate the Rights Plan earlier than such date if warranted.The Rights Plan is similar to other rights plans adopted by publicly held companies. Under the Rights Plan, the rights generally will become exercisable only if a person or group (including a group of persons who are acting in concert with each other) acquires beneficial ownership of 15% or more of Sharps Technology's common stock in a transaction not approved by Sharps Technology's Board of Directors. In that situation, each holder of a right (other than the acquiring person or group, whose rights will become void and will not be exercisable) will have the right to purchase, upon payment of the exercise price of $10.00 per right (both the exercise price and the number of shares for which a right is exercisable being subject to adjustment from time to time as set forth in the Rights Plan) and in accordance with the terms of the Rights Plan, a number of shares of Sharps Technology's common stock having a market value of twice such price. In addition, if Sharps Technology is acquired in a merger or other business combination after an acquiring person acquires 15% or more of Sharps Technology's common stock, each holder of the right would thereafter have the right to purchase, upon payment of the then-current exercise price and in accordance with the terms of the Rights Plan, a number of shares of common stock of the acquiring person having a market value of twice such price. The acquiring person or group will not be entitled to exercise these rights.Additional details regarding the Rights Plan are contained in the Company's Quarterly Report on Form 10-Q filed today with the U.S. Securities and Exchange Commission.Ellenoff Grossman & Schole LLP is serving as legal counsel to Sharps Technology.About Sharps TechnologySharps Technology is a medical device sales and distribution company focused on delivering best-in-class safety syringe solutions to the healthcare industry. The Company's current product offerings include ultra-low waste syringe technologies designed with active safety and re-use prevention features, underscoring its commitment to safer clinical outcomes and sustainable, eco-friendly product design.The Company has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.Forward-Looking StatementsThis press release contains certain forward-looking statements, including but not limited to those relating to the Company's Rights Plan. Forward-looking statements are based on the Company's current expectations and assumptions. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, among other factors, market and other conditions and risks identified from time to time in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's annual reports on Form 10-K, under the caption "Risk Factors."Contact
ir@sharpstechnology.com View original content to download multimedia:https://www.prnewswire.com/news-releases/sharps-technology-adopts-limited-duration-stockholder-rights-plan-302772955.htmlSOURCE Sharps Technology Inc Original: Sharps Technology Adopts Limited Duration Stockholder Rights Plan
subslover
9月前
Sharps Technology and Pudgy Penguins Announce Strategic Partnership
NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Sharps Technology ("Sharps Technology" or the "Company") (NASDAQ: STSS), a leading publicly listed Solana treasury, and Pudgy Penguins, the globally recognized Web3 brand, today announced a strategic partnership to bring exposure and connectivity to the Solana digital asset treasury space.
Pudgy Penguins has emerged as one of the most iconic and innovative brands in crypto—often called the internet's Mickey Mouse and Asia's $DOGE. With more than 220 billion content views and partnerships with major names including NASCAR, Walmart, and Lotte, Pudgy Penguins continues to bridge blockchain innovation with mainstream culture. Institutional recognition of the brand has also grown, highlighted by Canary's recent PENGU ETF filing.
The partnership represents another milestone for the team at STSS as it executes its highly differentiated digital asset treasury strategy. The Company recently acquired over two million SOL, valued north of $400 million and funded through a private investment in public equity (PIPE) transaction led by Cantor Fitzgerald & Co.
"We're excited to be collaborating with STSS, who have built one of the most institutionally recognized Solana treasuries in the market," said Luca Netz, CEO of Pudgy Penguins. "Verticalizing attention is important to the Pudgy Penguins thesis, and working with forward-thinking firms who see the value in culture, like STSS, will help accelerate the institutional adoption of Pudgy Penguins."
Through this collaboration, Pudgy Penguins' world-class IP will be integrated with STSS's institutional-grade Solana treasury, creating new opportunities for both retail and institutional audiences to engage with the Pudgy Penguins brand.
"Pudgy Penguins is one of the most widely recognized brands in Web3 and a cultural phenomenon that has captured millions globally," said James Zhang, Strategic Advisor to STSS. "Our partnership will create new and exciting ways for a broader audience to participate in the digital asset space."
Prudent Capitalist
9月前
Crazy share price action again today here (+31.3%). Just completed my 3d round trip flip for avg. gains per flip of $1.50 per share since the crazy 1-for-300 reverse split. Even wackier is the 52-week trading range for STSS of $3.39 - $2,164.52. But I am likely done with this circus, given the Board's ridiculous proxy item requesting an increase in the authorized shares from 1.167 million currently, with only 1.02 million shares outstanding post-RS, to 500,000.000 authorized shares which equates with 150 billion shares pre-RS. That is indefensible, and one must wonder what they intend to do if and when that passes.
Prudent Capitalist
1年前
Shorts are caught with their pants down this am.
Sharps Technology Begins First Shipments of Smart Safety Syringes For 3 Client Orders; Shares Up Pre-Bell
08:23:59 AM ET, 06/04/2025 - MT Newswires
08:23 AM EDT, 06/04/2025 (MT Newswires) -- Sharps Technology (STSS) said Wednesday it has initiated first shipments of its SecureGard and SoloGard smart safety syringes relating to three client orders from its manufacturing site in Hungary.
The company began shipment of its first commercial order of Sologard to a US-based IV flushing services provider under a previously announced $50 million agreement, while it has also delivered SecureGard syringes to a Hungarian vaccine provider after securing a $100,000 purchase order, Sharps said.
The total purchase commitments reached roughly $500,000 with the two orders, the company said.
The medical device and pharmaceutical packaging company also said it started a 200,000-unit shipment of 1mL low dead-volume syringes to a Switzerland-based global provider of cosmetic, dental, and ophthalmic injectable therapies.
Shares were up more than 53% in recent premarket activity.
Prudent Capitalist
1年前
You would have been cashed out. as you did not have sufficient shares for the RS. With 150 shares, and STSS closing at .02 the day before the RS, you should have received around $3.00. I found this example on-line:
For example, if a company does a reverse split of 100 shares to one, any shareholder who has fewer than 100 shares would not get a share. Instead, their shares would be exchanged for cash. For those investors, that means they no longer own a piece of a company.
corvatsch
1年前
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) – Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the receipt of a $400,000 purchase order from a U.S. leader in IV flushing solutions. This marks the first order under the previously announced $50 million supply agreement from July 2024.
“This order represents a transformative moment for Sharps Technology as we begin generating revenue and delivering on our commitment to shareholders,” said Robert Hayes, Chief Executive Officer of Sharps Technology. “Our strategic partnership is now moving from the agreement to the execution phase, with this initial order serving as the foundation for accelerating volume in the quarters ahead. Our Hungarian manufacturing facility is fully prepared to deliver these first orders of pump-compatible 10mL SoloGard syringes, allowing Sharps to recognize our first revenue of 2025. We look forward to advancing this supply agreement and delivering long-term value to our shareholders.”
The order initiates the landmark agreement announced in July 2024, under which Sharps will supply approximately 500 million customized 10mL SoloGard syringes to the U.S.-based supplier of medical saline and water products over a five-year period. The agreement is expected to generate approximately $50 million in revenue during its term.
Sharps has strategically invested in advanced production technology for SoloGard manufacturing and will soon begin installation and operational qualification to support increased production capacity. Sharps continues to work closely with the customer to finalize product qualification and optimize production processes to meet the growing demand anticipated under the agreement.